Verastem Presents Avutometinib and Defactinib Combination Pr

Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy Data

...

Related Keywords

United States , London , City Of , United Kingdom , Massachusetts , Boston , American , Udai Banerji , Dan Paterson , Jonathan Pachter , Louis Denis , Institute Of Cancer Research , Nasdaq , Drug Development Unit , Amgen , Drug Administration , Raf And Mek Program , American Society Of Clinical Oncology , Drug Development Summit , Verastem Oncology , Targeted Drug Development Summit , Chief Scientific Officer , Chief Medical Officer , Enhancing Antitumor Efficacy , Rational Combinations , Breakthrough Therapy Designation , Chief Executive Officer , Professor Udai Banerji , Deputy Director , Cancer Research , Royal Marsden , American Society , Clinical Oncology , Breakthrough Therapy , Markets ,